Huawei plans for more AI pharma tie-ups, says healthcare president

Huawei Pushes AI Drug Partnerships in China as Ascend Chips Power Domestic Push

William Zhang has a plan. The president of Huawei’s healthcare business unit told Reuters on Wednesday that the Chinese technology giant intends to expand its artificial intelligence collaborations with local drugmakers. The partnerships would stretch from compound screening into full drug development and clinical practice. “As we further deepen our research into AI in the medical field, we’ll have more collaboration and results emerging with ph…

Huawei plans more AI pharma partnerships, mainly with Chinese drugmakers

Huawei intends to sign more AI partnerships with pharmaceutical companies, according to William Zhang, president of its healthcare business unit, who told Reuters the projects currently run mainly with domestic Chinese drugmakers. The company sells compound screening tools alongside its Ascend and Kunpeng chips, the same domestic stack it has been building out since US […] This story continues at The Next Web

Huawei widens pharma hunt in AI race for new drugs

Technology conglomerate Huawei plans to expand its artificial intelligence cooperation with mainland pharmaceutical firms into drug development and clinical practice, a senior executive said. The move highlights Huawei's ambitions to gain a foothold in the fast-growing AI drug discovery market, where pharmaceutical companies are investing in modelling tools and automated laboratories to shorten development timelines and improve efficiency. "As w…

Huawei plans for more AI pharma tie-ups, says healthcare president

SHANGHAI, Aug 27 : Chinese technology conglomerate Huawei plans to expand its AI cooperation with local pharmaceutical firms into drug development and clinical practice, a senior executive said.The move highlights Huawei's ambitions to gain a foothold in the fast-growing AI drug discovery market, where pharma